

10/519388 #2

DT01 Rec'd PCT/FTC 23 DEC 2004

Express Mail #EV582746869US

Attorney Docket # 1739-10PUS

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re National Phase PCT Application of

Helmut SCHMIDHAMMER et al.

Int'l PCT Serial No.: PCT/EP2003/006866

Int'l Filing Date:: 27 June 2003

For: Morphinan Derivatives The Quaternary
Ammonium Salts Thereof Substituted In
Position 14, Method For Production And
Use Thereof

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also enclosed.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in § 1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

10/519388
DT01 Rec'd 10/PTC 23 DEC 2004

It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By Thomas C. Pontani
Thomas C. Pontani
Reg. No. 29,763
551 Fifth Avenue, Suite 1210
New York, New York 10176
(212) 687-2770

Dated: December 23, 2004

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number /

DT01 Recd PCT/PCT 23 DEC 2004

Substitute for Form 1449/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/519388
		Filing Date	
		First Named Inventor	Helmut SCHMIDHAMMER
		Art Unit	
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	1739-10PUS

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ , Number ⁴ , Kind-Code ⁵ (if known)				
		UK 1,300,419	12/20/72	W. R. Buckett et al.		
		EP 0 250 796	1/7/88	E. I. Du Pont De Nemours and Co.		
		DE 3412727 A1	10/17/85	A. Gleich		
		EP 0 030 685 A2	6/24/81	R. K. Razdan et al.		
		WO2004/005294 A2	1/15/04	H. Schmidhammer et al.		

Examiner Signature _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Standard Form 17. If possible, Applicant is to place a check mark here if an English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you needed assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DT01 Rec'd PCT/FT 23 DEC 2004

Substitute for Form 1449/PTO		<i>Complete if Known</i> 10/15/19388	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Helmut SCHMIDHAMMER
		Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	1739-10PUS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chen-Yu Cheng, et al., "N-Cubylmethyl Substituted Morphinoids as Novel Narcotic Antagonists", <u>Bioorganic & Medicinal Chemistry</u> , Vol. 4, No. 1, pp 73-80, 1996.	
		A. Coop, et al., "Delta Opioid Binding Selectivity of 3-Ether Analogs of Naltrindole", <u>Bioorganic & Medicinal Chemistry Letters</u> , 9 (1999) 3435-3438.	
		J. Schütz, et al., "Synthesis and Biological Evaluation of 14-Alkoxy morphinans. 17. Highly δ Opioid Receptor Selective 14-Alkoxy-Substituted Indolo- and Benzofuromorphinans", <u>J. Med. Chem.</u> , 2002, 45, 5378-5383.	
		H. Schmidhammer, et al., "Synthesis and Biological Evaluation of 14-Alkoxy morphinans. 1. Highly Potent Opioid Agonists in the Series of (-) - 14 Methoxy- <i>N</i> -methylmorphinan-6-ones", <u>J. Med. Chem.</u> , 1964, 27, 1575-1579.	
		P. Klein, et al., " O^3 -(2-Carbomethoxyallyl) Ethers of Opioid Ligands Derived from Oxymorphone, Naltrexone, Etorphine, Diprenorphine, Norbinaltorphimine, and Naltrindole. Unexpected O^3 -Dealkylation in the Opioid Radioligand Displacement Assay", <u>J. Med. Chem.</u> , 1992, 35, 4589-4594.	
		P.S. Portoghesi, et al., "Synthesis of Naltrexone-Dervied δ -Opioid Antagonists. Role of Conformation of the δ Address Moiety", <u>J. Med. Chem.</u> , 1994, 37, 579-585.	
		C. W. Funke, et al., "A ¹ H and ¹³ C Nuclear Magnetic Resonance Study of Three Quaternary Salts of Naloxone and Oxymorphone", <u>J. Chem. Soc. Perkin Trans. II</u> , 1986, Pages 735-738.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-9100 (1-800-786-9100) and select option 2.